trial

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

NCTId NCT05526833
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 3 (actual)
Sponsored by Columbia University
Primary completion 2023-01-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
3 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2022-09-12
Primary completion
2023-01-24
Eligibility
ALL · 22 Years · 55 Years

Interventions & indications

Drugs
repetitive Transcranial Magnetic Stimulation (rTMS)

Sponsors

Columbia UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Michael Avissar, MD, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
3
Phase
NA
Primary Completion Date
2023-01-24
Status
TERMINATED
relationships
The graph out of here
drug
repetitive Transcranial Magnetic Stimulation (rTMS)
drug
lead_sponsor
Columbia University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia and Related Disorders
indication
Hallucinations
indication
Schizophrenia
indication
investigator
Michael Avissar, MD, PhD
person